MedTrace Logo

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)

NCT01050634 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 980

Last updated 2010-07-23

Study results available
· View outcomes & findings →

Summary

Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire.

Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).

Deeper knowledge of Adverse Events during routine administration.

Conditions

  • Post Menopausal Women With Early Breast Cancer

Interventions

DRUG

Aromasin (exemestane)

25mg oral tablet, daily, for \>1yr

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-04-30
Completion
2009-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050634 on ClinicalTrials.gov